DE602004032265D1 - Herstellungsverfahren von medizinischen zusammensetzungen - Google Patents

Herstellungsverfahren von medizinischen zusammensetzungen

Info

Publication number
DE602004032265D1
DE602004032265D1 DE602004032265T DE602004032265T DE602004032265D1 DE 602004032265 D1 DE602004032265 D1 DE 602004032265D1 DE 602004032265 T DE602004032265 T DE 602004032265T DE 602004032265 T DE602004032265 T DE 602004032265T DE 602004032265 D1 DE602004032265 D1 DE 602004032265D1
Authority
DE
Germany
Prior art keywords
biocompatible polymer
sup
acylated
carboxylic acid
terminal carboxylic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004032265T
Other languages
English (en)
Inventor
John T Capecchi
James S Stefely
Peter M Seiler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of DE602004032265D1 publication Critical patent/DE602004032265D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • C08G63/912—Polymers modified by chemical after-treatment derived from hydroxycarboxylic acids
DE602004032265T 2003-12-30 2004-12-10 Herstellungsverfahren von medizinischen zusammensetzungen Active DE602004032265D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53317203P 2003-12-30 2003-12-30
PCT/US2004/041194 WO2005066238A1 (en) 2003-12-30 2004-12-10 Medicinal compositions and method for the preparation thereof

Publications (1)

Publication Number Publication Date
DE602004032265D1 true DE602004032265D1 (de) 2011-05-26

Family

ID=34748864

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004032265T Active DE602004032265D1 (de) 2003-12-30 2004-12-10 Herstellungsverfahren von medizinischen zusammensetzungen

Country Status (9)

Country Link
US (1) US7597897B2 (de)
EP (1) EP1699847B1 (de)
JP (1) JP2007517032A (de)
CN (1) CN1902254A (de)
AT (1) ATE505503T1 (de)
AU (1) AU2004312336A1 (de)
CA (1) CA2552139A1 (de)
DE (1) DE602004032265D1 (de)
WO (1) WO2005066238A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005290068A1 (en) * 2004-09-24 2006-04-06 3M Innovative Properties Company Medicinal aerosol formulations and methods of synthesizing ingredients therefor
EP2968359B1 (de) * 2013-03-12 2021-01-20 Celltaxis, LLC Verfahren zur hemmung einer leukotrien-a4-hydrolase
EP2968264A4 (de) 2013-03-14 2016-11-02 Celtaxsys Inc Inhibitoren der leukotrien-a4-hydrolase
AU2019278935A1 (en) 2018-05-31 2020-12-10 Celltaxis, Llc Method of reducing pulmonary exacerbations in respiratory disease patients

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2714454B2 (ja) 1988-11-07 1998-02-16 三井東圧化学株式会社 生体吸収性ポリエステルの製造方法
DE3917617A1 (de) 1989-05-31 1990-12-06 Boehringer Ingelheim Kg Mikronisierte bioabbaubare partikel, verfahren zur ihrer herstellung und ihre verwendung
JPH04226125A (ja) 1990-06-23 1992-08-14 Boehringer Ingelheim Kg ポリ−ｄ，ｌ−ラクチドの製造方法及び活性物質の担体としてのそれらの使用
ES2122261T3 (es) * 1993-03-17 1998-12-16 Minnesota Mining & Mfg Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester.
US5618911A (en) 1993-08-19 1997-04-08 Toyo Boseki Kabushiki Kaisha Polymer containing lactic acid as its constituting unit and method for producing the same
JPH0959218A (ja) 1995-08-25 1997-03-04 Shimadzu Corp Ｌ−乳酸オリゴマー誘導体
JPH09124778A (ja) 1995-10-31 1997-05-13 Shimadzu Corp ポリ乳酸の製造法
CA2250981C (en) 1996-04-23 2002-07-02 Kinerton Limited Acidic polylactic polymers
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
DE60222007T2 (de) 2001-10-18 2008-05-15 Samyang Corp. Polymermicellenzusammensetzung mit verbesserter stabilität
JP2005505675A (ja) * 2001-10-18 2005-02-24 サムヤン コーポレイション 高分子ミセルを形成するｐＨ応答性生分解性ポリ乳酸誘導体及び難溶性薬物伝達体への当該誘導体の使用

Also Published As

Publication number Publication date
WO2005066238A1 (en) 2005-07-21
CN1902254A (zh) 2007-01-24
EP1699847B1 (de) 2011-04-13
EP1699847A1 (de) 2006-09-13
JP2007517032A (ja) 2007-06-28
CA2552139A1 (en) 2005-07-21
US20080267885A1 (en) 2008-10-30
US7597897B2 (en) 2009-10-06
ATE505503T1 (de) 2011-04-15
AU2004312336A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
NO20000573D0 (no) Kjemiske forbindelser
BR9916585A (pt) Moduladores de ccr5
BR9905977A (pt) Moduladores de ccr5
BR9917007A (pt) Moduladores de ccr5
CY1106032T1 (el) Υποκατασταθεισες πυραζολες
NZ523957A (en) 6.alpha., 9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4-diene-17-carbothioic acid S-fluoromethyl ester as an anti-inflammatory agent
BRPI0413728A (pt) muteìnas de lipocalina da lágrima
TR200102910T2 (tr) èeker artìklarìyla ikame edilmiç 1,4-benzotiyazepin-1,1-dioksid trevleri
ECSP034430A (es) Esteres oxigenados de acidos 4-yodo fenilamino benzhidroxamcios
ATE246202T1 (de) Gcsf konjugate
PA8548801A1 (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
DE60237986D1 (de) Polymer auf basis von konjugierten dienen, herstellungsverfahren dafür und dieses enthaltende kautschukzusammensetzungen
BR9808998A (pt) Imidazóis substituìdos úteis no tratamento de doenças inflamatórias
DE60001546D1 (de) Liponsaürederivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
MEP43408A (en) Novel fluorene carboxylic acid esters, methods for the production thereof, and use of the same as pharmaceuticals
NO20056161L (no) Formuleringer for behandling av artrittilstander
ATE491475T1 (de) Konjugate enthaltend gm-csf und ein polymer
WO2004028272A3 (en) Injectable growth promoting and anthelmintic composition
ECSP055803A (es) Ésteres de ácido carbámico con actividad anticolinérgica
DE60232158D1 (de) Lipopeptid-stereoisomere, verfahren zu ihrer herstellung und nützliche zwischenprodukte
BRPI0410861A (pt) métodos e composições para a produção de aminoácidos
BR0009139A (pt) Dispositivos médicos lúbricos
DE50113943D1 (de) 4-alkoxy-cyclohexan-1-amino-carbonsäureester und verfahren zu ihrer herstellung
DE602004032265D1 (de) Herstellungsverfahren von medizinischen zusammensetzungen
CY1105345T1 (el) Φαινυλαλκινια